Skip to content
Screener

Eton Pharmaceuticals, Inc. ETON EV / EBITDA

EV / EBITDA at other companies

HRO
HarrowHROW
70.8×-139×
XER
Xeris Biopharma Holdings, Inc.XERS
40.5×—
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
7.7×-10.6×
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
7.9×—
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
4.3×-1.7×
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
16.4×-5.2×

Other financials

Income statement

See full
Revenue$24.3M+40.4%
Gross profit$14.7M+49.4%
Operating income$2.4M+614%
Net income$1.6M+199%
EPS (diluted)$0.05+183%

Balance sheet

See full
Cash & equivalents$19.7M+12.9%
Total debt$31.3M+3.7%
Total equity$30.6M+25.2%
Total assets$97.7M+16.3%

Cash flow

See full
Operating cash flow$7.4M+254%
CapEx$75.0K—
Free cash flow$7.3M+251%

Valuation

See full
Market cap$1.26B+167%
Enterprise value$1.28B+167%
P/S14.6×+6.4×

Profitability

See full
Gross margin54.8%-3.7pp
Operating margin-15.1%—
Net margin-9.5%-2.7pp
FCF margin17.1%—

Returns & leverage

See full
Return on equity-34.2%+0.9pp
Debt / equity1×-0.2×
Current ratio1.2×-0.8×

Where this comes from

Calculated from Eton Pharmaceuticals, Inc.’s reported figures.

enterprise value/ebitda=525.2×

Based on the most recent quarter.

The source filing: Eton Pharmaceuticals, Inc.’s 10-Q, filed August 7, 2025. Open the filing →

Filed
Aug 7, 2025
Fiscal quarter
Q2 FY2025
Calendar quarter
Q2 2025
Accession
0001437749-25-025444

FAQ

What is Eton Pharmaceuticals, Inc.'s EV / EBITDA?
Eton Pharmaceuticals, Inc. (ETON) reported EV / EBITDA of 525.2× in Q2 2025.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.

Ask your AI about Eton Pharmaceuticals, Inc.'s ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude